Related Experiment Videos
[5-fluorouracil and dihydropyrimidine dehydrogenase]
1Department of Surgery, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|May 2, 2001
Summary
Dihydropyrimidine dehydrogenase (DPD) inhibitors offer a new era in oral chemotherapy. These DPD inhibitory fluoropyrimidines (DIFs) reduce 5-fluorouracil toxicity and improve treatment efficacy.
Area of Science:
- Biochemistry and Pharmacology
- Enzymology
- Cancer Therapeutics
Context:
- Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the catabolism of fluoropyrimidines.
- DPD activity influences the toxicity and efficacy of 5-fluorouracil (5-FU) chemotherapy.
- Tumoral DPD levels are a predictive marker for response to 5-FU-based therapies.
Purpose:
- To review the role of DPD in 5-FU pharmacology.
- To discuss the development and importance of DPD inhibitory fluoropyrimidines (DIFs).
- To highlight the impact of DIFs on oral 5-FU therapy.
Summary:
- DPD is the rate-limiting enzyme in fluoropyrimidine breakdown, significantly impacting 5-FU pharmacodynamics.
- DPD inhibitory fluoropyrimidines (DIFs) have been developed to modulate DPD activity.
- These novel agents aim to reduce 5-FU toxicity and enhance its therapeutic effectiveness.
Impact:
- DIFs represent a significant advancement in oral 5-FU chemotherapy.
- This new class of drugs promises to minimize inter-patient variability in 5-FU response.
- DIFs contribute to improved patient outcomes by enhancing efficacy and reducing toxicity in 5-FU-based treatments.